394 related articles for article (PubMed ID: 29108908)
1. Tofacitinib 2% ointment, a topical Janus kinase inhibitor, for the treatment of alopecia areata: A pilot study of 10 patients.
Liu LY; Craiglow BG; King BA
J Am Acad Dermatol; 2018 Feb; 78(2):403-404.e1. PubMed ID: 29108908
[No Abstract] [Full Text] [Related]
2. Tofacitinib for the treatment of alopecia areata and variants in adolescents.
Craiglow BG; Liu LY; King BA
J Am Acad Dermatol; 2017 Jan; 76(1):29-32. PubMed ID: 27816292
[TBL] [Abstract][Full Text] [Related]
3. Tofacitinib for the treatment of severe alopecia areata and variants: A study of 90 patients.
Liu LY; Craiglow BG; Dai F; King BA
J Am Acad Dermatol; 2017 Jan; 76(1):22-28. PubMed ID: 27816293
[TBL] [Abstract][Full Text] [Related]
4. Successful Treatment of Severe Alopecia Areata With Oral or Topical Tofacitinib.
Cheng MW; Kehl A; Worswick S; Goh C
J Drugs Dermatol; 2018 Jul; 17(7):800-803. PubMed ID: 30005104
[TBL] [Abstract][Full Text] [Related]
5. Treatment of Alopecia Areata With Tofacitinib.
Ibrahim O; Bayart CB; Hogan S; Piliang M; Bergfeld WF
JAMA Dermatol; 2017 Jun; 153(6):600-602. PubMed ID: 28355451
[TBL] [Abstract][Full Text] [Related]
6. Janus Kinase Inhibitors for the Treatment of Severe Alopecia Areata: An Open-Label Comparative Study.
Almutairi N; Nour TM; Hussain NH
Dermatology; 2019; 235(2):130-136. PubMed ID: 30566941
[TBL] [Abstract][Full Text] [Related]
7. Effectiveness and safety of generic tofacitinib in alopecia areata: is the generic a cost-effective option? A retrospective study.
Jian J; Li M; Qian P; Li J; Tang Y; Liu F; Zhao Z; Huang J; Shi W
Arch Dermatol Res; 2024 May; 316(5):154. PubMed ID: 38734794
[No Abstract] [Full Text] [Related]
8. Oral tofacitinib: a promising treatment in atopic dermatitis, alopecia areata and vitiligo.
Vu M; Heyes C; Robertson SJ; Varigos GA; Ross G
Clin Exp Dermatol; 2017 Dec; 42(8):942-944. PubMed ID: 29034491
[No Abstract] [Full Text] [Related]
9. Topical tofacitinib in treatment of alopecia areata.
Ferreira SB; Ferreira RB; Scheinberg MA
Einstein (Sao Paulo); 2020; 18():eAI5452. PubMed ID: 32785452
[No Abstract] [Full Text] [Related]
10. Treatment of an alopecia areata patient with tofacitinib results in regrowth of hair and changes in serum and skin biomarkers.
Jabbari A; Nguyen N; Cerise JE; Ulerio G; de Jong A; Clynes R; Christiano AM; Mackay-Wiggan J
Exp Dermatol; 2016 Aug; 25(8):642-3. PubMed ID: 27119625
[No Abstract] [Full Text] [Related]
11. Therapeutic synergy between contact dermatitis from a wig-fixing device and tofacitinib on alopecia areata.
Lee JS; Yoon HS; Cho S; Park HS
J Dermatol; 2019 Apr; 46(4):e139-e140. PubMed ID: 30204259
[No Abstract] [Full Text] [Related]
12. Tofacitinib therapy for children with severe alopecia areata.
Dai YX; Chen CC
J Am Acad Dermatol; 2019 Apr; 80(4):1164-1166. PubMed ID: 30630026
[No Abstract] [Full Text] [Related]
13. Successful Treatment of Refractory Alopecia Areata Universalis and Psoriatic Arthritis, But Not of Plaque Psoriasis with Tofacitinib in a Young Woman.
Mrowietz U; Gerdes S; Gläser R; Schröder O
Acta Derm Venereol; 2017 Feb; 97(2):283-284. PubMed ID: 27349217
[No Abstract] [Full Text] [Related]
14. Nail involvement in patients with moderate-to-severe alopecia areata treated with oral tofacitinib.
Lee JS; Huh CH; Kwon O; Yoon HS; Cho S; Park HS
J Dermatolog Treat; 2018 Dec; 29(8):819-822. PubMed ID: 29658800
[TBL] [Abstract][Full Text] [Related]
15. Response of alopecia areata of the beard to oral tofacitinib.
Kerkemeyer KLS; John JM; Sinclair R; Bhoyrul B
J Am Acad Dermatol; 2020 May; 82(5):1228-1230. PubMed ID: 31678329
[No Abstract] [Full Text] [Related]
16. Treatment of alopecia universalis with topical Janus kinase inhibitors - a double blind, placebo, and active controlled pilot study.
Bokhari L; Sinclair R
Int J Dermatol; 2018 Dec; 57(12):1464-1470. PubMed ID: 30160787
[TBL] [Abstract][Full Text] [Related]
17. Clinical experiences on alopecia areata treatment with tofacitinib: A study of 63 patients.
Serdaroğlu S; Engin B; Çelik U; Erkan E; Aşkın Ö; Oba Ç; Kutlubay Z
Dermatol Ther; 2019 May; 32(3):e12844. PubMed ID: 30693634
[No Abstract] [Full Text] [Related]
18. Topical Janus kinase inhibitors for the treatment of pediatric alopecia areata.
Bayart CB; DeNiro KL; Brichta L; Craiglow BG; Sidbury R
J Am Acad Dermatol; 2017 Jul; 77(1):167-170. PubMed ID: 28619556
[No Abstract] [Full Text] [Related]
19. Rebound effect associated with JAK inhibitor use in the treatment of alopecia areata.
Gordon SC; Abudu M; Zancanaro P; Ko JM; Rosmarin D
J Eur Acad Dermatol Venereol; 2019 Apr; 33(4):e156-e157. PubMed ID: 30520145
[No Abstract] [Full Text] [Related]
20. An Open-Label Pilot Study to Evaluate the Efficacy of Tofacitinib in Moderate to Severe Patch-Type Alopecia Areata, Totalis, and Universalis.
Jabbari A; Sansaricq F; Cerise J; Chen JC; Bitterman A; Ulerio G; Borbon J; Clynes R; Christiano AM; Mackay-Wiggan J
J Invest Dermatol; 2018 Jul; 138(7):1539-1545. PubMed ID: 29452121
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
